We designed an ELISA with full-length AIRE protein to evaluate AIRE reactivity in a validation cohort that consisted of serum samples from 26 anti-Mi2 autoantibody-positive DM patients, 44 myositis patients with other MSAs or IBM, and 63 healthy comparators (Table 1). This evidence concerns the gene AIRE and dermatomyositis.